First author of the article - Riten Kumar/LinkedIn
Dec 9, 2025, 13:27
Riten Kumar: Highlights From Day 2 of ASH25
Riten Kumar, Associate Professor of Pediatrics at Harvard Medical School and Director of Thrombosis and Anticoagulation at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, shared on LinkedIn:
“Highlights of day 2 of ASH25 – excellent lectures on PFD and HHT, long term data on gene therapy and altuviiio in hemophilia. Particularly enjoyed the the session on arterial thrombosis for hematologists. Interesting data on iv iron infection. It was also great to see some of the work from the ASH/ISTH guidelines work get presented…… And of course, hematologists can groove!”
All from ASH25 featured in Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies